enVVeno Medical Corp. Files Supervisory Appeal After FDA Issues Not-Approvable Letter for VenoValve® PMA; Ongoing Regulatory Review Continues
Reuters
Sep 26
<a href="https://laohu8.com/S/NVNO">enVVeno Medical Corp.</a> Files Supervisory Appeal After FDA Issues Not-Approvable Letter for VenoValve® PMA; Ongoing Regulatory Review Continues
**enVVeno Medical Corp. Requests FDA Supervisory Appeal for VenoValve® Approval** Irvine, CA, September 26, 2025 - enVVeno Medical Corp. (NASDAQ: NVNO) has announced it is pursuing a supervisory appeal with the U.S. Food & Drug Administration (FDA) following the receipt of a not-approvable letter from the agency's Center for Devices and Radiological Health (CDRH) regarding its Premarket Approval (PMA) application for the VenoValve®. The VenoValve® is a surgical replacement venous valve designed to treat severe deep chronic venous insufficiency $(CVI)$. No new grant or funding has been reported, and the regulatory review pertains solely to enVVeno Medical Corp.'s device. CEO Robert Berman discussed the ongoing regulatory process during a recent Virtual Investor "What This Means" segment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enVVeno Medical Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1078504) on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.